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Abstract
Purpose—Our Pediatric Endocrinology Clinic has seen a sharp increase in referrals for gender 
dysphoria (GD) during recent years. However, the frequency and characteristics of referrals have 
not been objectively examined.
Methods—A retrospective chart review of referrals for GD during the past 13 years was 
performed. Variables analyzed included numbers of referrals per year, patient characteristics, 
comorbid conditions, and hormonal therapy. Timing of referral and eligibility for treatment were 
measured against established recommendations.
Results—Of 38 patients, 74% were referred during the last 3 years. Most patients presented late 
in puberty before a GD-specific psychological evaluation and few were eligible for hormonal 
treatment at baseline. Over half had psychiatric and/or developmental comorbidities.
Conclusions—A dramatic increase in referrals for GD since 2002 was confirmed. Enhanced 
provider education and outreach regarding care of patients with GD are needed.
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Gender dysphoria (GD) is characterized by cross-gender identification and distress 
associated with a patient’s natal gender [1]. For those choosing medical intervention, 
treatment involves gradual physical and social transition to the identified gender. This 
requires collaboration between medical professionals and mental health providers (MHP). 
Guidelines for treatment and monitoring are available through the Endocrine Society and 
World Professional Association for Transgender Health and encompass criteria for children 
and youth [2,3]. Although referral to specialized gender clinics is ideal, this may not be 
feasible for many families due to financial and travel constraints.
Criteria for hormonal treatment of GD include confirmation of the diagnosis and 
recommendation for treatment by a qualified MHP. A real-life experience (RLE) of living 
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full-time in the identified gender is also considered necessary before cross-sex hormone 
therapy. Puberty suppression is reversible and may be prescribed as early as Tanner stage II, 
whereas cross-sex hormones bring about partially irreversible physical changes. Although 
traditionally considered at age 16 years, there is a growing trend toward beginning this step 
as early as age 14 years [3].
There has been a perceived escalation in the frequency of referrals for GD to our Pediatric 
Endocrinology clinic in recent years. However, whether this has actually been the case has 
not been systematically examined. We also sought to characterize our referrals with respect 
to patient readiness for hormonal treatment at the time of presentation to our clinic.
Methods
After institutional review board approval, a retrospective review was performed to identify 
all patients seen in our Pediatric Endocrine clinic between January 1, 2002 and April 1, 2015 
for “GD,” “gender identity disorder,” or “gender identity.” Variables analyzed included age 
and pubertal status at presentation, documentation of a psychological evaluation for GD, 
history of RLE, concurrent diagnoses, type and timing of puberty suppression, and cross-sex 
hormones. Population frequencies were compared using a chi-square test with a two-tailed p 
value, where applicable. All other population frequencies are expressed as a percentage.
Results
A total of 38 patients (81.6% Caucasian) aged 14.4 ± 3.2 years were identified, consisting of 
16 natal males and 22 natal females (p = .33), with 73.6% presenting since January 1, 2013. 
Thirty-one (81.6%) were Tanner stage IV or V at baseline whereas six (15.8%) were 
prepubertal and one (2.6%) was in early puberty. Of natal females, 86% were 
postmenarchal.
At presentation, 29% of patients had received a GD-specific psychological evaluation and 
recommendation for treatment. Anecdotally, several families mentioned difficulty in finding 
an MHP, particularly in rural areas. In contrast, 57.9% of patients had pursued an RLE.
Fifteen patients received puberty suppression at 15.5 ± 2.1 years. Nine were approved for 
first-line treatment in the form of gonadotropin-releasing hormone analogs (GnRHa), 
whereas six were denied necessitating second-line alternatives. These consisted of 
progestins in natal females and an androgen receptor blocker in natal males. Of patients 
receiving puberty suppression, eight were treated with cross-sex hormones at 16.2 ± 1.4 
years.
Of the entire cohort, 24 (63.1%) had concurrent psychiatric and/or developmental diagnoses. 
These consisted of depression in 31.6%, attention deficit/hyperactivity disorder in 15.8% 
and autism spectrum disorder in 13.1%. Five patients (13.1%) had a history of suicidality 
and/or self-harm. Patient characteristics and treatment course are outlined in the Table 1.
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Discussion
Referrals for GD have reportedly surged at many centers [4]. The remarkable increase in the 
number of new patients seen in our clinic over the last 3 years has occurred even though our 
referral base is unchanged, and our clinic has not specifically advertised its care for 
transgender patients. Previous reports are usually from established multidisciplinary gender 
clinics. That our general endocrinology clinic has also seen a marked rise in referrals 
highlights the rising demand for services.
The reason for the increase in referrals is unknown. With greater media attention to 
lesbian/gay/bisexual/transgender/queer issues and gender-nonconforming celebrities, 
patients may find it easier to access information regarding transition. Greater visibility and 
social acceptance of being transgendered may also facilitate patients’ ability to express their 
gender identity to friends and family. Publication of the 2009 Endocrine Society treatment 
guidelines and several high-profile lawsuits may have increased provider awareness.
Despite the availability of practice guidelines [2,3], most of our patients are referred before a 
GD-specific psychological evaluation. This likely represents a knowledge deficit regarding 
criteria for hormonal treatment on the part of referring providers. A shortage of MHP 
qualified to address this specialized issue is also a contributing factor for our patients and 
has been reported as a common barrier to transgender care elsewhere [5]. Even within our 
large tertiary care children’s hospital, psychological services for GD are woefully lacking. 
Similarly, nearly half of our patients had not yet pursued an RLE at the time of their first 
clinic visit. Finally, most arrive in late puberty despite guidelines allowing for puberty 
suppression as early as Tanner stage II. This negatively impacts physical outcomes due to 
lost opportunity to modulate final adult height and the development of secondary sexual 
characteristics including breast development in natal females and low voice, Adam’s apple 
development, and masculine facial features in natal males [4,6,7].
Our clinic encountered several patients with autism spectrum disorders and a high rate of 
psychological comorbidity, consistent with previous reports [4,8]. Although not all 
conditions are likely a consequence of GD, this nevertheless underscores the need for 
psychological services for this population, regardless of the stage of gender transition. It 
should be noted that 40% of our patients who met criteria for pubertal suppression were 
denied insurance approval for GnRHa, possibly related to off-label use. This represents a 
lack of awareness on the part of insurers regarding the serious nature of GD and high risk of 
depression and suicidality in affected children and adolescents who are denied psychological 
support and treatment [8–10].
In conclusion, our results confirm a drastic increase in the incidence of referrals for GD and 
the high rate of psychiatric and developmental issues in this population. Despite their 
advanced pubertal stage, only a minority of our patients met criteria for hormonal treatment 
at presentation. Thus, our findings also highlight the need for targeted education of referring 
providers and greater availability of psychological services. If the observed amplification in 
the diagnosis of GD continues, routine training of pediatric providers in standards of care for 
the management of gender nonconforming-children will be essential.
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IMPLICATIONS AND CONTRIBUTION
There has been a dramatic increase in referrals for gender dysphoria, even outside of 
specialized centers. Most patients arrive late in puberty without having fulfilled necessary 
criteria to begin hormonal treatment, resulting in a delay in care. The population has a 
high rate of psychiatric and developmental comorbidities.
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Table 1
Referral characteristics and treatment
All patients, n = 38
Affirmed gender, n p = .33
 MTF 16
 FTM 22
(1 Gender
fluid)
Pubertal status, n (%)
 Postmenarchal 19 (86.4%)
  Tanner IV or V 31 (81.6%)
  Tanner II or III 1 (2.6%)
  Pre-pubertal 6 (15.8%)
BMI SDS Overall: .77 ± 1.11
  MTF .56 +/− 1.35
  FTM .93 +/− .90
Ethnicity
 Caucasian 30 (78.9%)
 Asian 2 (5.3%)
 African American 2 (5.3%)
 Biracial 2 (5.3%)
 Other/unknown 2 (5.3%)
Psychological
 evaluation at
 baseline, n (%)
 No 27 (71%)
 Yesa 11 (28.9%)
RLE, n (%)
 No 16 (42.1%)
 Yes 22 (57.9%)
Concurrent diagnoses
 at baseline, n (%)
 Autism spectrum 5 (13.1%)
 ADD/ADHD 6 (15.8%)
 Psychiatric diagnoses 18 (47.4%)
  Depression 12 (31.6%)
  History of self-harm/
suicide attempt
5 (13.1%)
  Psychotropic
medications
14 (36.8%)
Treated patients, n = 15 MTF
(n = 5)
FTM
(n = 10)
Age (mean ± SD)
Pubertal suppression 15.5 ± 2.1 year
 GnRHa 2 7
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All patients, n = 38
 Progestins 0 3
Androgen receptor
blocker
3 0
Cross-gender therapy 16.2 ± 1.4 year
4 4
ADD/ADHD = attention deficit/hyperactivity disorder; BMI = body mass index;
FTM = female-to-male; GnRHa = gonadotropin-releasing hormone analogs;
MTF = male-to-female; RLE = real-life experience; SD = standard deviation;
SDS = standard deviation score.
aOne received an evaluation from a social worker, and the remainder received an evaluation from a clinical psychologist.
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